SNDX
Price
$12.57
Change
-$0.15 (-1.18%)
Updated
Aug 8, 10:55 AM (EDT)
Capitalization
1.1B
95 days until earnings call
YMAB
Price
$8.51
Change
-$0.01 (-0.12%)
Updated
Aug 8, 11:02 AM (EDT)
Capitalization
387.14M
90 days until earnings call
Interact to see
Advertisement

SNDX vs YMAB

Header iconSNDX vs YMAB Comparison
Open Charts SNDX vs YMABBanner chart's image
Syndax Pharmaceuticals
Price$12.57
Change-$0.15 (-1.18%)
Volume$100
Capitalization1.1B
Y-mAbs Therapeutics
Price$8.51
Change-$0.01 (-0.12%)
Volume$9.49K
Capitalization387.14M
SNDX vs YMAB Comparison Chart in %
Loading...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SNDX vs. YMAB commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNDX is a Buy and YMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (SNDX: $12.72 vs. YMAB: $8.52)
Brand notoriety: SNDX and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNDX: 103% vs. YMAB: 163%
Market capitalization -- SNDX: $1.1B vs. YMAB: $387.14M
SNDX [@Biotechnology] is valued at $1.1B. YMAB’s [@Biotechnology] market capitalization is $387.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNDX’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • SNDX’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both SNDX and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNDX’s TA Score shows that 6 TA indicator(s) are bullish while YMAB’s TA Score has 6 bullish TA indicator(s).

  • SNDX’s TA Score: 6 bullish, 4 bearish.
  • YMAB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both SNDX and YMAB are a good buy in the short-term.

Price Growth

SNDX (@Biotechnology) experienced а +28.23% price change this week, while YMAB (@Biotechnology) price change was +90.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.21%. For the same industry, the average monthly price growth was +6.59%, and the average quarterly price growth was +12.79%.

Reported Earning Dates

SNDX is expected to report earnings on Nov 11, 2025.

YMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.1B) has a higher market cap than YMAB($387M). YMAB YTD gains are higher at: 8.812 vs. SNDX (-3.782). YMAB has higher annual earnings (EBITDA): -30.39M vs. SNDX (-318.27M). SNDX has more cash in the bank: 516M vs. YMAB (60.3M). YMAB has less debt than SNDX: YMAB (603K) vs SNDX (1.84M). YMAB has higher revenues than SNDX: YMAB (88.7M) vs SNDX (43.7M).
SNDXYMABSNDX / YMAB
Capitalization1.1B387M283%
EBITDA-318.27M-30.39M1,047%
Gain YTD-3.7828.812-43%
P/E RatioN/AN/A-
Revenue43.7M88.7M49%
Total Cash516M60.3M856%
Total Debt1.84M603K305%
FUNDAMENTALS RATINGS
SNDX vs YMAB: Fundamental Ratings
SNDX
YMAB
OUTLOOK RATING
1..100
8331
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4235
P/E GROWTH RATING
1..100
4100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (45) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNDX (85) in the Biotechnology industry. This means that YMAB’s stock grew somewhat faster than SNDX’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SNDX (100) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

YMAB's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as SNDX (98) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

YMAB's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as SNDX (42) in the Biotechnology industry. This means that YMAB’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for YMAB (100) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew significantly faster than YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNDXYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 22 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCAYX11.66N/A
N/A
Invesco Income Advantage U.S. Fund Y
NQCRX5.44N/A
N/A
Nuveen Large Cap Value Opportunities I
MKVFX16.32N/A
N/A
MFS International Large Cap Value R3
HCMPX18.58N/A
N/A
HCM Sector Plus Investor
JRSIX12.57-0.01
-0.08%
JH Adaptive Risk Mgd U.S. Eq I

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with CGON. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-1.32%
CGON - SNDX
52%
Loosely correlated
-3.80%
IDYA - SNDX
52%
Loosely correlated
-5.16%
REPL - SNDX
51%
Loosely correlated
-0.36%
ACLX - SNDX
50%
Loosely correlated
-1.24%
RNA - SNDX
48%
Loosely correlated
-1.53%
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with SNDX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then SNDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
N/A
SNDX - YMAB
45%
Loosely correlated
-1.32%
IDYA - YMAB
45%
Loosely correlated
-5.16%
RXRX - YMAB
44%
Loosely correlated
-1.28%
NUVB - YMAB
44%
Loosely correlated
-0.43%
AURA - YMAB
41%
Loosely correlated
-1.21%
More